How PCORnet® Could Advance Postmarket Evidence Generation

PCORnet® 如何促进上市后证据的生成

阅读:1

Abstract

The PCORnet vision to accelerate progress towards a learning health system by enabling more efficient generation of evidence is shared by the US Food and Drug Administration, where we recently served. One way of achieving this goal is to develop national networks capable of running streamlined clinical trials in the postmarket setting. In this invited commentary, we discuss how PCORnet® and similar networks could facilitate streamlined trials integrated into clinical practice across their sites.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。